Bristol-Myers Squibb (NYSE:BMY) has submitted its marketing application to the FDA seeking approval of CAR T therapy lisocabtagene maraleucel (liso-cel) (formerly JCAR017) for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL) who have received at least two prior therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.